Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Cancer Chemother Pharmacol. 2016 Feb;77(2):439. doi: 10.1007/s00280-015-2890-9.

¹ Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA. [email protected].
² University of California, 2020 Santa Monica Blvd., Suite 600, Santa Monica, CA, 90404, USA.
³ Dana-Farber Cancer Institute, 450 Brookline Ave., Dana 1602, Boston, MA, 02215, USA.
⁴ Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
⁵ Taiho Oncology Inc., 202 Carnegie Center, Suite 100, Princeton, NJ, 08540, USA.
⁶ Taiho Pharmaceutical of Beijing Co., Ltd., 9F-9A3, Hanwei Plaza, 7th, Guanghua Rd., Chaoyang Dist., Beijing City, 100004, China.
⁷ Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL, 34232, USA.

No abstract available

Publication types